Pharmacokinetic and Pharmacodynamic Evaluation of a Novel Proton Pump Inhibitor, YH1885, in Healthy Volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 1, 2004, Pages 73-82

  Yu, Kyung Sang ^a   Bae, Kyun Seop ^c   Shon, Ji Hong ^d   Cho, Joo Youn ^a   Yi, So Young ^a   Chung, Jae Yong ^a   Lim, Hyeong Seok ^b   Jang, In Jin ^a,b   Shin, Sang Goo ^a,b   Song, Keun Seog ^e   Moon, Byoung Seok ^e  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Asan Medical Center   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Yuhan Corporation   (South Korea)

Author keywords

Gastric acid related diseases; Pharmacokinetics; Proton pump inhibitors; YH1885

Indexed keywords

PLACEBO; PROTON PUMP INHIBITOR; REVAPRAZAN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTRIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INDIGESTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MULTIPLE DRUG DOSE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STOMACH DISEASE; STOMACH PH; THROAT DISEASE; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; DRUG EVALUATION; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; METABOLIC CLEARANCE RATE; PROTON PUMPS; PYRIMIDINONES; TETRAHYDROISOQUINOLINES;

EID: 10744220360     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003261321     Document Type: Article

References (29)

1. Klotz U: Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000;38(3):243-270.
2. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K: Acid, protons and Helicobacter pylori. Yale J Biol Med 1996;69(3):301-316.
3. Bensancon M, Simon A, Sachs G, Shin JM: Sites of reaction of the gastric H,KATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272(36):22438-22446.
4. Langtry HD, Wilde MI: Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 1998;56(3):447-486.
5. Matheson AJ, Jarvis B: Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001;61(12):1803-1835.
6. Garnett WR: Lansoprazole: a proton pump inhibitor. Ann Pharmacother 1996;30(12):1425-1436.
7. Fitton A, Wiseman L: Pantoprazole: a review of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1996;51(3):460-482.
8. Jungnickel PW: Pantoprazole: a new proton pump inhibitor. Clin Ther 2000;22(11):1268-1293.
9. Langtry HD, Markham A: Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999;58(4):725-742.
10. Carswell CI, Goa KL: Rabeprazole: an update of its use in acid-related disorders. Drugs 2001;61(5):2327-2356.
11. Johnson TJ, Hedge DD: Esomeprazole: a clinical review. Am J Health Syst Pharm 2002;59(14):1333-1339.
12. Tonini M, Vigneri S, Savarino V, Scarpignato C: Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 2001;33(7):600-606.
13. Horn J: The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22(3):266-280.
14. Han KS, Kim YG, Yoo JK, Lee JW, Lee MG: Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm Drug Dispos 1998;19(8):493-500.
15. Han KS, Choi HC, Yoo JK, Lee JW, Lee MG: Determination of a new proton pump inhibitor, YH1885, in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;696(2):312-316.
16. Fackler WK, Vaezi MF, Richter JE: Ambulatory gastric pH monitoring: proper probe placement and normal values. Aliment Pharmacol Ther 2001;15(8):1155-1162,
17. Mela GS, Savarino V, Vigneri S: Optimizing the information obtained from continuous 24-hour gastric pH monitoring. Am J Gastroenterol 1992;87(8):961-966.
18. Bell NJ, Hunt RH: Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther 1996;10(6):897-904.
19. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL: The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997;24(2):65-70.
20. Lew EA, Barbuti RC, Kovacs TO, Sytnic B, Humphries TJ, Walsh JH: An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 1998;12(7):667-672.
21. Timmer W, Wehling M, Theiss U: 24-hour recording of intragastric pH in clinical trials: preconditions, methodology, and standardization strategies. J Clin Pharmacol 1997;37(1, Suppl.):34S-39S.
22. Katz PO: Lessons learned from intragastric pH monitoring. J Clin Gastroenterol 2001;33(2):107-113.
23. Brunner G, Hell M, Hengels KJ, Hennig U, Fuchs W: Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Digestion 1995;56(2):137-144.
24. Kuo B, Castell DO: Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996;91(8):1532-1538.
25. Berlin RG: Omeprazole: gastrin and gastric endocrine cell data from clinical studies. Dig Dis Sci 1991;36(2):129-136.
26. Malaty HM, Kim JG, Kim SD, Graham DY: Prevalence of Helicobacter pylori infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 1996;143(3):257-262.
27. Chang WK, Kim HY, Kim DJ, Lee J, Park CK, Yoo JY, et al: Association between Helicobacter pylori infection and the risk of gastric cancer in the Korean population: prospective case-controlled study. J Gastroenterol 2001;36(12):816-822.
28. Choe YH, Hwang S, Hong YC: Higher seroprevalence of Helicobacter pylori infection in Korean adolescent athletes compared to age- and sex-matched nonathletes. J Gastroenterol Hepatol 2002;17(2):131-134.
29. van Herwaarden MA, Samsom M, Smout AJ: 24-h recording of intragastric pH: technical aspects and clinical relevance. Scand J Gastroenterol Suppl 1999;230:9-16.